Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Real-world patterns of secondary malignancies and relapse following CAR T-cell therapy: A faers pharmacovigilance analysis

View Full Paper
Ask AI
Bookmark
Share

Authors

SSSheilabi SeeburunMCMohamad Cherry

Discussion

Loading...

Member takes

Overview

Pharmacovigilance analysis reveals adverse events linked to CAR T-cell therapy, indicating a need for enhanced monitoring of malignancies.

Key Points

  • Secondary malignancies occurred in 19.9% of adverse events linked to CAR T-cell therapy.
  • Among 13,685 reported events, 1,226 were related to Axi-cel, showing a distinct product-specific pattern.
  • Retrospective pharmacovigilance analysis of FAERS reports highlighted recurrence and unique neoplasms after therapy.
  • Identifying the risks of myelodysplastic syndromes underscores the importance of vigilant surveillance post-treatment.

Cite This Study

Seeburun et al. (2025) studied this question.

synapsesocial.com/papers/69362f744fa91c937236e27fhttps://doi.org/10.1182/blood-2025-7669
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Treatment-Related Myelodysplastic Syndrome and Acute Myeloid Leukemia Associated with CAR T-Cell Therapies : A Real-World FAERS Pharmacovigilance Study2026
  2. 2A post-marketing pharmacovigilance analysis of cardiotoxicities following chimeric antigen receptor T-cell therapy using the FDA adverse event reporting system2025
  3. 3Endocrine adverse events following CAR-T cell therapies: A pharmacovigilance analysis in the real-world setting utilizing the faers database2025
  4. 4Comparative real-world outcomes of CD19-directed CAR T-cell therapies in large B-cell lymphoma2025 · 21 citations
  5. 5Association of CAR T cell kinetics with outcomes after standard of care brexucabtagene autoleucel for relapsed/refractory Mantle Cell Lymphoma2025